Evolution of the Average Target: Compass Therapeutics, Inc.

Evolution of the Average Target - Compass Therapeutics, Inc.

Evolution of the Target Price: Compass Therapeutics, Inc.

Evolution of the Target Price - Compass Therapeutics, Inc.

Changes in Analyst Recommendations: Compass Therapeutics, Inc.

0b36dfff.x6pN0w8TBU_XbND6flg7qEk349rv6JN1yXJ8ZOYQmBI.qNwllGp-MyCzKuaKSwtcnxFAzr-Eh8kkhEYbJoNdtU316D2VaEtGIpM9vw~1932ecf29f9b5d7870658d4b5901ba45
09-23 Compass Therapeutics Shares Drop After Downgrade From Wedbush MT
09-23 Wedbush Downgrades Compass Therapeutics to Neutral From Outperform, Cuts Price Target to $1 From $5 MT
04-28 Raymond James Downgrades Compass Therapeutics to Market Perform From Outperform MT
04-27 Wedbush Lowers Compass Therapeutics Price Target to $5 From $8, Maintains Outperform Rating MT
01-05 William Blair Initiates Compass Therapeutics at Outperform MT
12-03 Canaccord Genuity Initiates Compass Therapeutics at Buy With $10 Price Target MT
12-03 Cantor Fitzgerald Initiates Compass Therapeutics at Overweight MT
02/04/25 Leerink Partners Upgrades Compass Therapeutics to Outperform From Market Perform, Adjusts PT to $6 From $4 MT
24/02/25 Guggenheim Initiates Compass Therapeutics at Buy With $12 Price Target MT
19/02/25 Piper Sandler Initiates Compass Therapeutics at Overweight MT
16/09/24 Ladenburg Thalmann Upgrades Compass Therapeutics to Buy From Neutral MT
31/01/23 Jefferies Starts Compass Therapeutics at Buy With $8 Price Target MT
27/01/23 Stifel Initiates Compass Therapeutics at Buy With $9 Price Target MT
16/12/22 EF Hutton Initiates Compass Therapeutics at Buy With $10.30 Price Target MT
10/11/22 Raymond James Adjusts Price Target on Compass Therapeutics to $8 From $5, Maintains Outperform Rating MT
03/11/22 HC Wainwright Adjusts Compass Therapeutics' Price Target to $10 From $12, Keeps Buy Rating MT
23/05/22 HC Wainwright Assumes Compass Therapeutics at Buy, Price Target Set at $12 MT
05/05/22 SVB Leerink Adjusts Compass Therapeutics' Price Target to $11 from $9, Keeps Outperform Rating MT
15/03/22 Ladenburg Thalmann Initiates Compass Therapeutics at Buy With $7 Price Target MT
19/01/22 B. Riley Starts Compass Therapeutics at Buy with $10 PT, Says Well-Positioned to Benefit from Potential Biotech Sector Turnaround MT
22/12/21 Raymond James Starts Compass Therapeutics at Outperform With $5 Price Target MT
20/12/21 SVB Leerink Starts Compass Therapeutics at Outperform With $12 Price Target MT
15/12/21 Wedbush Starts Compass Therapeutics at Outperform With $8 Price Target MT
19/11/21 Roth Capital Initiates Compass Therapeutics at Buy Rating With $15 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+508.29%
+24.19%
+33.33%
+14.65%
+10.55%
+36.95%
+16.48%
+47.08%
+22.87%
+29.34%
Average +74.37%
Weighted average by Cap. +25.38%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
0.8967USD
Average target price
5.455USD
Spread / Average Target
+508.29%
High Price Target
12.00USD
Spread / Highest target
+1,238.24%
Low Price Target
1.000USD
Spread / Lowest Target
+11.52%

Analyst Consensus Detail

Analyst consensus - Compass Therapeutics, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Compass Therapeutics, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Compass Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. CMPX Stock
  4. Consensus Compass Therapeutics, Inc.